Irish drugmaker Elan is considering a separate stock exchange
listing for its contract services unit, Elan Drug Technology,
according to comments by executives at its recent annual general
meeting.
In the face of generic competition, Abbott has asked Irish
biotechnology firm Elan to use its NanoCrystal technology to
develop an "all in one" oral dose formulation combining two
cholesterol drugs, AstraZeneca's Crestor...
US biotechnology company Biogen Idec has succumbed to the effects
of having to withdraw its multiple sclerosis drug Tysabri
(natalizumab) earlier this year, cutting 17 per cent of its
workforce and putting manufacturing facilities...
Ireland's largest home grown pharmaceutical company, Elan Holdings,
could be split up into two separate units, one focussing on
biotechnology and the other on manufacturing and drug delivery,
according to UK news reports.
Ireland's Elan has signed its first major contract manufacturing
and supply agreement in a development that reinforces its
credentials as a player in the outsourcing sector.
Ireland's Elan has said that its US-based drug delivery business,
NanoSystems, will not be part of the sell-off in assets forced by
its onerous debt burden. The company is also retaining its US acute
care products business.
Ireland's Elan Corp has inked a deal with Ingenium Pharmaceuticals
of Germany that will see the companies apply Ingenium's functional
genomics technologies to the discovery and development of novel
therapeutics for pain...
